• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不可治愈的 IV 期结直肠癌患者姑息性原发肿瘤切除术后生存的预测预后因素。回顾性队列研究。

Prognostic factors predicting survival in incurable stage IV colorectal cancer patients who underwent palliative primary tumor resection. Retrospective cohort study.

机构信息

Department of Surgery, Nowon Eulji Medical Center, Eulji University College of Medicine, Seoul, Republic of Korea.

Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University, College of Medicine, Seoul, Republic of Korea.

出版信息

Int J Surg. 2018 Jan;49:10-15. doi: 10.1016/j.ijsu.2017.11.038. Epub 2017 Dec 1.

DOI:10.1016/j.ijsu.2017.11.038
PMID:29198632
Abstract

BACKGROUND

The aim of this study is to estimate prognostic factors predicting survival in patients with incurable stage IV colorectal cancer (CRC), who underwent palliative primary tumor resection (PTR) with chemotherapy.

MATERIALS AND METHODS

We retrospectively performed an analysis using clinicopathological parameters of 103 patients with incurable stage IV CRC, who underwent palliative PTR with chemotherapy between 2006 and 2010. Prognostic factors associated with overall survival (OS) were evaluated by univariate and multivariate analyses.

RESULTS

The median follow-up time was 17.5 months (range 2.4-60.5) for the total cohort (n = 103). There were five independent factors related to OS in univariate analysis (body mass index, tumor differentiation, pT, pN stage and local clearance of the primary tumor). A multivariate analysis revealed that pT, pN and local clearance of the primary tumor were prognostic factors related to OS. Median survival months (95% CI) were pT1, 2, 3: 21.5 (16.23-26.77) months vs. pT4: 13.73 (9.94-17.53) months, pN-: 29.7 (22.55-35.99) months vs. pN+: 17.1 (15.0-19.41) months and R0: 18.57 (16.65-20.48) months vs. R1, 2: 12.43 (9.95-14.91) months.

CONCLUSION

Locally advanced primary tumor (high pT stage, positive regional lymph node, and local residual primary tumor) was associated with poorer OS in incurable stage IV CRC patients, who underwent palliative PTR with chemotherapy. The PTR appears to result in better OS in patients with a primary tumor that is not locally advanced.

摘要

背景

本研究旨在评估姑息性原发肿瘤切除术(PTR)联合化疗治疗不可治愈的 IV 期结直肠癌(CRC)患者的生存预后相关因素。

材料与方法

我们回顾性分析了 2006 年至 2010 年间 103 例接受姑息性 PTR 联合化疗的不可治愈 IV 期 CRC 患者的临床病理参数。通过单因素和多因素分析评估与总生存期(OS)相关的预后因素。

结果

全队列(n=103)的中位随访时间为 17.5 个月(范围 2.4-60.5)。单因素分析中有 5 个与 OS 相关的独立因素(体质指数、肿瘤分化、pT、pN 分期和原发肿瘤局部清除)。多因素分析显示,pT、pN 和原发肿瘤局部清除是与 OS 相关的预后因素。中位生存月数(95%CI)为 pT1、2、3:21.5(16.23-26.77)个月 vs. pT4:13.73(9.94-17.53)个月,pN-:29.7(22.55-35.99)个月 vs. pN+:17.1(15.0-19.41)个月,R0:18.57(16.65-20.48)个月 vs. R1、2:12.43(9.95-14.91)个月。

结论

不可治愈的 IV 期 CRC 患者姑息性 PTR 联合化疗后,局部进展期原发肿瘤(高 pT 分期、阳性区域淋巴结和局部残留原发肿瘤)与较差的 OS 相关。对于局部未进展的原发肿瘤患者,PTR 似乎能带来更好的 OS。

相似文献

1
Prognostic factors predicting survival in incurable stage IV colorectal cancer patients who underwent palliative primary tumor resection. Retrospective cohort study.不可治愈的 IV 期结直肠癌患者姑息性原发肿瘤切除术后生存的预测预后因素。回顾性队列研究。
Int J Surg. 2018 Jan;49:10-15. doi: 10.1016/j.ijsu.2017.11.038. Epub 2017 Dec 1.
2
Survival outcomes following primary tumor resection for patients with incurable metastatic colorectal carcinoma: Experience from a single institution.不可治愈的转移性结直肠癌患者行原发灶切除术后的生存结局:单中心经验。
J Dig Dis. 2018 Sep;19(9):550-560. doi: 10.1111/1751-2980.12657. Epub 2018 Oct 4.
3
Modern-day palliative chemotherapy for metastatic colorectal cancer: does colonic resection affect survival?现代转移性结直肠癌的姑息化疗:结肠切除术会影响生存率吗?
ANZ J Surg. 2018 Nov;88(11):E772-E777. doi: 10.1111/ans.14726. Epub 2018 Jun 25.
4
Laparoscopic versus conventional palliative resection for incurable, symptomatic stage IV colorectal cancer: impact on short-term results.腹腔镜手术与传统姑息性切除术治疗无法治愈的有症状的IV期结直肠癌:对短期结果的影响
Surg Laparosc Endosc Percutan Tech. 2011 Jun;21(3):184-7. doi: 10.1097/SLE.0b013e31821db75e.
5
Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: A nationwide population-based propensity-score adjusted study in the Netherlands.对无法治愈的IV期结直肠癌进行原发肿瘤姑息性切除与总体生存率提高相关:荷兰一项基于全国人群的倾向评分调整研究
Int J Cancer. 2016 Nov 1;139(9):2082-94. doi: 10.1002/ijc.30240. Epub 2016 Jul 12.
6
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.结直肠癌合并同期不可切除转移患者行原发灶切除的临床意义。
J Surg Oncol. 2014 Aug;110(2):214-21. doi: 10.1002/jso.23607. Epub 2014 Mar 26.
7
Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis.原发性肿瘤位置作为不可切除转移结直肠癌姑息性切除获益的预测因素
World J Surg Oncol. 2017 Jul 27;15(1):138. doi: 10.1186/s12957-017-1198-0.
8
Surgical Resection of the Primary Tumor in Stage IV Colorectal Cancer Without Metastasectomy is Associated With Improved Overall Survival Compared With Chemotherapy/Radiation Therapy Alone.与单纯化疗/放疗相比,IV期结直肠癌患者在未行转移灶切除术时进行原发肿瘤的手术切除与总生存期改善相关。
Dis Colon Rectum. 2016 Apr;59(4):299-305. doi: 10.1097/DCR.0000000000000546.
9
Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent.姑息性治疗的转移性结直肠癌患者的原发肿瘤切除与总生存期
Clin Colorectal Cancer. 2016 Sep;15(3):e125-32. doi: 10.1016/j.clcc.2015.12.010. Epub 2015 Dec 29.
10
Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases.与先进行原发性肿瘤切除然后对不可切除的同步转移结直肠癌进行化疗相比, upfront全身化疗是一种可行的选择。 (注:“upfront”在这里可理解为“ upfront”,有“在开始时、预先”等意思 )
World J Surg Oncol. 2015 Apr 24;13:162. doi: 10.1186/s12957-015-0570-1.

引用本文的文献

1
Survival benefits of primary tumor resection in metastatic differentiated thyroid cancer: an analysis of SEER data.转移性分化型甲状腺癌原发肿瘤切除的生存获益:基于监测、流行病学和最终结果(SEER)数据的分析
Sci Rep. 2025 Jul 1;15(1):21932. doi: 10.1038/s41598-025-08845-y.
2
Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.贝伐珠单抗联合 FOLFIRI 一线治疗伴同步不可切除转移的转移性结直肠癌患者中,无症状原发肿瘤切除对生存获益的影响。
Int J Colorectal Dis. 2024 Oct 25;39(1):171. doi: 10.1007/s00384-024-04745-1.
3
Primary tumor resection in colorectal cancer patients with unresectable distant metastases: a minireview.
不可切除远处转移的结直肠癌患者的原发肿瘤切除术:一篇综述
Front Oncol. 2023 Apr 27;13:1138407. doi: 10.3389/fonc.2023.1138407. eCollection 2023.
4
Immunohistochemical Expression of Stanniocalcin 2 in Colorectal Cancer: A Retrospective Egyptian Study.钙调素2在结直肠癌中的免疫组化表达:一项埃及回顾性研究
Iran J Pathol. 2022 Winter;17(1):15-22. doi: 10.30699/IJP.2021-.521799.2559. Epub 2021 Dec 15.
5
Prognostic and predictive values of tumour budding in stage IV colorectal cancer.肿瘤芽在 IV 期结直肠癌中的预后和预测价值。
BJS Open. 2020 Aug;4(4):693-703. doi: 10.1002/bjs5.50300. Epub 2020 May 29.
6
Endoscopic placement of pancreatic stent for "Deep" pancreatic enucleations operative technique and preliminary experience at two high-volume centers.内镜下胰腺支架置入术在“深部”胰腺切除术的应用:两大学术中心的手术技术和初步经验。
Surg Endosc. 2020 Jun;34(6):2796-2802. doi: 10.1007/s00464-020-07501-y. Epub 2020 Mar 16.
7
The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy.接受含贝伐单抗化疗的不可切除的IV期结直肠癌患者原发肿瘤切除的结果。
Medicine (Baltimore). 2020 Feb;99(7):e19258. doi: 10.1097/MD.0000000000019258.